Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders

A study published in Cancer Cell has identified a novel population of PTGER3-positive cancer-associated fibroblasts (CAFs) that emerge specifically in bladder cancer patients who respond to neoadjuvant chemotherapy. These chemotherapy-induced fibroblasts undergo lipid oxidation reprogramming and actively enhance CD8+ T cell function, thereby remodeling the tumor microenvironment and restraining tumor progression. The finding provides a mechanistic explanation for why some patients benefit from pre-surgical chemotherapy while others do not. This discovery could eventually inform biomarker development to predict chemotherapy response and guide therapeutic strategies aimed at enhancing anti-tumor immune activity in bladder cancer.